Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
FGF2 2247 PENTOSAN POLYSULFATE SODIUM CHEMBL1201516 antagonist TdgClinicalTrial, NCI, TEND, DrugBank 7692072, 10667230, 8738610, 12375053, 17071728
FGF2 2247 SIROLIMUS CHEMBL413 TdgClinicalTrial, DrugBank 12742462
FGF2 2247 Sucralfate CHEMBL2367706 agonist DrugBank 1970337, 7948825, 8578218, 1957124, 8578198
FGF2 2247 FAMOTIDINE CHEMBL902 NCI 11943947
FGF2 2247 FULVESTRANT CHEMBL1358 NCI 12566092
FGF2 2247 VINCRISTINE CHEMBL90555 NCI 8988045
FGF2 2247 MUPARFOSTAT (CHEMBL1615835) CHEMBL1615835 inhibitor ChemblInteractions
FGF2 2247 CHEMBL262489 CHEMBL262489 NCI, DrugBank 16051960
FGF2 2247 EDARAVONE CHEMBL290916 NCI 10452107
FGF2 2247 PYRAZOLE CHEMBL15967 NCI 9730230
FGF2 2247 ASPIRIN CHEMBL25 NCI 9071932
FGF2 2247 QUIZARTINIB CHEMBL576982 CIViC 27671675
FGF2 2247 MEDRONIC ACID CHEMBL180570 NCI 12005179, 9824986
FGF2 2247 CAFFEINE CHEMBL113 NCI 15738284
FGF2 2247 ESTRADIOL DIPROPIONATE CHEMBL1697791 NCI 8862495
FGF2 2247 ATORVASTATIN CHEMBL1487 NCI 12147302
FGF2 2247 INDOMETHACIN CHEMBL6 NCI 9071932
FGF2 2247 PHENYLEPHRINE CHEMBL1215 NCI 15875663
FGF2 2247 THYROTROPIN CHEMBL1201532 NCI 7519916
FGF2 2247 TRIAMCINOLONE CHEMBL1451 NCI 15923512
FGF2 2247 REBAMIPIDE CHEMBL1697771 NCI 8774986

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
FGF2 rs1960669 A bevacizumab efficacy no Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele C. 28045923 1448995800
FGF2 rs308395 CG + GG lenalidomide efficacy yes Genotypes CG + GG is associated with decreased response to lenalidomide or thalidomide in people with Multiple Myeloma as compared to genotype CC. 28373444 1448612673
FGF2 rs1449683 CC + CT fluvoxamine efficacy yes depressive symptoms measured on Hamilton Rating Scale for Depression and outcome as change in symptoms, as measured 6 weeks after drug, following 10 days washout. Genotypes CC + CT are associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to genotype TT. 25710119 1447681357